BRCA1 and ovarian carcinoma: Similarly, in September 2020, the Ministry approved niraparib as a maintenance treatment for patients with newly diagnosed, platinum-sensitive epithelial ovarian cancer, regardless of BRCA1 or BRCA2 status.